Semaglutide

GLP-1 receptor agonist · Also known as Ozempic, Wegovy, Rybelsus

What is Semaglutide?

A synthetic peptide that mimics GLP-1, a naturally occurring hormone your body produces after eating. It works by telling your brain you're full, slowing digestion, and helping regulate blood sugar levels.

Originally developed for type 2 diabetes (marketed as Ozempic), semaglutide gained widespread attention when clinical trials showed remarkable weight loss results. It's now also available as Wegovy, specifically approved for chronic weight management.

Key takeaway: Semaglutide has the strongest clinical evidence of any weight loss peptide, with 15-17% average body weight reduction in major clinical trials.

Benefits & evidence

Weight loss High confidence
Blood sugar control High confidence
Cardiovascular health Moderate confidence
Appetite suppression High confidence
Neuroprotection Preliminary confidence

How it works

Think of GLP-1 as your body's natural "I'm full" signal. When you eat, your gut releases GLP-1, which tells your brain to stop eating and signals your pancreas to manage blood sugar. The problem? Natural GLP-1 breaks down in minutes.

Semaglutide is engineered to last much longer. about a week. It binds to the same GLP-1 receptors but resists the enzymes that normally break it down. The result is a steady, sustained signal that helps reduce appetite, slow gastric emptying, and improve insulin sensitivity.

Dosing information

Typical dosing protocol
Starting dose

0.25 mg/week

Weeks 1-4
Maintenance dose

1.0-2.4 mg/week

After titration period

Doses are gradually increased over 16-20 weeks to minimize side effects. Always follow your prescriber's instructions.

Side effects

Most side effects tend to improve as your body adjusts.

Nausea Common
Diarrhea Common
Constipation Common
Headache Moderate
Pancreatitis Rare

Research (98 studies)

Early Adoption and Prescribing Patterns of Resmetirom: A Multi-Institutional National Analysis. Liver international : official journal of the International Association for the Study of the Liver · 2026
Semaglutide Hype or Hope: Evidence-based Review in Diabesity. The Journal of the Association of Physicians of India · 2026
National Consensus on Semaglutide in Cardiology: From Clinical Evidence to Clinical Translation. The Journal of the Association of Physicians of India · 2026
Tirzepatide-Induced Liver Injury: A Rare Complication. AACE endocrinology and diabetes · 2026
Semaglutide-Associated Sequential Unilateral Transient Osteoporosis of The Hip: A Case Report. American journal of physical medicine & rehabilitation · 2026
Glucagon-Like Peptide-1 Receptor Agonist Utilization Among Sleep Surgery Clinic Patients. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2026
Childhood Obesity, Medications, and Surgeries. Cardiology in review · 2026
Glucagon-Like Peptide-1 Receptor Agonists: Their Potential Role in Prediabetes. Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
Widespread exposure to GLP-1RAs and weight loss-related discourse: Considering potential public health implications. Canadian journal of public health = Revue canadienne de sante publique · 2026
Repeated semaglutide treatment attenuates cocaine-vs-food choice in male and female rats. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
Complex clinical encounter series: Glucagon-like peptide-1 receptor agonists-induced weight loss: are we paying attention to bone health? Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2026
Differential Effects of Semaglutide and Colchicine on Atrial Remodeling in Rats with Reduced Ejection Fraction after Myocardial Infarction. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
Semaglutide for obesity management: A narrative review of efficacy, safety, and future directions. Journal of the American Pharmacists Association : JAPhA · 2026
Cardiovascular outcomes of glucagon-like peptide-1 receptor agonists: A systematic review. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2026